TITLE

The effect of bevacizumab on colon anastomotic healing in rats

AUTHOR(S)
Pavlidis, Efstathios T.; Ballas, Konstantinos D.; Symeonidis, Nikolaos G.; Psarras, Kyriakos; Koliakos, Georgios; Kouzi-Koliakos, Kokona; Topouridou, Konstantina; Rafailidis, Savas F.; Pavlidis, Theodoros E.; Marakis, Georgios N.; Sakantamis, Athanasios K.
PUB. DATE
December 2010
SOURCE
International Journal of Colorectal Disease;Dec2010, Vol. 25 Issue 12, p1465
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose: The aim of the study was to investigate the effect of angiogenesis inhibition by bevacizumab, a monoclonal anti-vascular endothelial growth factor (VEGF) antibody, on the healing process of colonic anastomoses in rats, assessing some specific involved factors. This new agent is used mainly in metastatic colorectal cancer. The angiogenesis plays an important role in both wound healing and metastatic invasion and spread of malignant cells. There has not been any evidence assessing the optimal time for its safe use in operated patients. Materials and methods: Forty Wistar rats were randomly allocated into four equal groups. A colonic anastomosis was performed in all rats. Half of them received intraoperatively a single dose of bevacizumab 5 mg/body weight and the rest received placebo. The animals were sacrificed on the 7th (Avastin 7th, placebo 7th) and 14th (Avastin 14th, placebo1 4th) postoperative day. The anastomosis was resected and sent for histological study and for tissue biochemical assays (VEGF, endothelin-1 (ET-1), C-reactive protein (CRP), pro-oxidant-antioxidant balance (PAB), carbonylated proteins, hydroxyproline) using specific enzyme-linked immunosorbent assay kits. For statistical analysis, the Mann-Whitney U test was used (of statistical significance when P < 0.05). Results: No complication or anastomotic dehiscence was observed. Histology did not reveal statistically significant differences between groups concerning degree of inflammation, fibroblasts, collagen, and fibrosis. Likewise, hydroxyproline levels did not differ. However, some statistically significant differences were found in VEGF, CRP and carbonyl proteins (Avastin 7th vs placebo 7th, placebo 14th vs placebo 7th), ET-1, and PAB (Avastin 14th vs Avastin 7th), which did not finally affect the collagen synthesis marker hydroxyproline, nor did the anastomotic strength. Conclusions: Bevacizumab, when administered intraoperatively, has no significant effect on colon anastomotic healing in rats despite a transient mild ischemia.
ACCESSION #
55024329

 

Related Articles

  • Colorectal Cancer: RESULTS FROM THE PHASE III TML TRIAL. Di Valentin, Tanya // Oncology Exchange;Aug2012, Vol. 11 Issue 3, p27 

    The article discusses a study which investigated the second line use of standard computed tomography (CT) and bevacizumab (BEV) in treating metastatic colorectal cancer (mCRC). It states BEV inhibits vascular endothelial growth factor A (VEGF-A), which promotes tumour angiogenesis. It notes that...

  • Continuum of care with anti-angiogenic therapies in metastatic colorectal cancer. Smaglo, Brandon G.; Hwang, Jimmy // Journal of Gastrointestinal Oncology;Sep2013, Vol. 4 Issue 3, p299 

    Inhibition of tumor angiogenesis has emerged as an important therapeutic component in the management of metastatic colorectal cancer. Three anti-angiogenic agents are currently approved in this clinical setting: bevacizumab, ziv-aflibercept, and regorafenib. Bevacizumab, a monoclonal antibody...

  • Cardiovascular Safety of VEGF-Targeting Therapies: Current Evidence and Handling Strategies. Girardi, Fabio; Franceschi, Enrico; Brandes, Alba A. // Oncologist;Jul2010, Vol. 15 Issue 7, p683 

    Treatment with the angiogenesis inhibitors bevacizumab, sunitinib, and sorafenib as single agents or in combination with conventional chemotherapy is becoming a cornerstone of modern anticancer therapy. However, the potential toxicity of these drugs, mainly to the cardiovascular system, is still...

  • Bevacizumab Attenuates Hepatic Fibrosis in Rats by Inhibiting Activation of Hepatic Stellate Cells. Huang, Yangqing; Feng, Helin; Kan, Tong; Huang, Bin; Zhang, Minfeng; Li, Yesheng; Shi, Changying; Wu, Mengchao; Luo, Yunquan; Yang, Jiamei; Xu, Feng // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    Angiogenesis is a fundamental part of the response to tissue injury, which is involved in the development of hepatic fibrosis. Vascular endothelial growth factor plays an important role in angiogenesis. The expression of VEGF is increased during hepatic fibrogenesis and correlates with the...

  • Oncology Nursing in a New Era: Optimizing Treatment With Bevacizumab. Marrs, Joyce; Zubal, Beth A. // Clinical Journal of Oncology Nursing;Oct2009, Vol. 13 Issue 5, p564 

    Overexpression of vascular endothelial growth factor (VEGF) by tumor cells promotes angiogenesis, which correlates with progressive tumor growth and poor outcomes in many types of cancer. Bevacizumab inhibits VEGF to promote regression of tumor vessels by limiting blood supply and tumor growth,...

  • Managing patients with metastatic colorectal cancer on bevacizumab. Lemmens, Liesbeth; Claes, Viviane; Uzzell, Maggie // British Journal of Nursing;8/14/2008, Vol. 17 Issue 15, p944 

    Bevacizumab (Avastin®) is a humanized monoclonal antibody that inhibits the activity of vascular endothelial growth factor (VEGF), a key molecule controlling tumour blood vessel formation (angiogenesis). By inhibiting VEGF and thus tumour angiogenesis, bevacizumab inhibits tumour growth and...

  • Nanoparticle-Mediated Expression of an Angiogenic Inhibitor Ameliorates Ischemia-Induced Retinal Neovascularization and Diabetes-Induced Retinal Vascular Leakage. Park, Kyoungmin; Chen, Ying; Hu, Yang; Mayo, Aaron S.; Kompella, Uday B.; Longeras, Richard; Ma, Jian-xing // Diabetes;Aug2009, Vol. 58 Issue 8, p1902 

    OBJECTIVE--The aim of the study is to evaluate the effect of nanoparticle-mediated gene delivery of angiogenic inhibitors on retinal inflammation, vascular leakage, and neovascularization in diabetic retinopathy. RESEARCH DESIGN AND METHODS--An expression plasmid of plasminogen kringle 5 (K5), a...

  • A novel adverse effect: bevacizumab induced tooth loss. Holley, Kristina D.; Larck, Chris; Chowdhary, Aneel; Sehgal, Rajesh // Cancer Therapy;2011, Vol. 8, p155 

    Bevacizumab is a recombinant humanized monoclonal antibody that binds and neutralizes vascular endothelial growth factor (VEGF). The anti-angiogenic effects of bevacizumab have been well described in the literature. In this case report, we describe a 53-year-old female with metastatic colorectal...

  • Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Ronzoni, M.; Manzoni, M.; Mariucci, S.; Loupakis, F.; Brugnatelli, S.; Bencardino, K.; Rovati, B.; Tinelli, C.; Falcone, A.; Villa, E.; Danova, M. // Annals of Oncology;Dec2010, Vol. 21 Issue 12, p2382 

    Background: Despite the consistent clinical results demonstrated by studies on anti-angiogenic drugs targeted against the vascular endothelial growth factor in metastatic colorectal cancer (mCRC) patients, no specific direct/indirect biomarker of their efficacy has been validated. In this field,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics